Efficacy of Rituximab Combined With Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy
Status:
Recruiting
Trial end date:
2023-12-04
Target enrollment:
Participant gender:
Summary
Idiopathic membranous nephropathy (IMN) is one of the common types of primary glomerular
diseases and the most common cause of nephrotic syndrome in adults.
Poticelli regimen is the classic treatment, but cyclophosphamide has many toxic side effects.
The period of glucocorticoid therapy is relatively long, and the adverse reactions caused by
glucocorticoid therapy cannot be ignored. For patients who are unwilling to receive
glucocorticoids and cyclophosphanide or who have treatment contraindications, cyclosporine
can be used, mainly cyclosporine and tacrolimus, with the rapid overall effect but a high
short-term relapse rate. In recent years, rituximab therapy has become a first-line
treatment, with a high remission rate, and few side effects, but expensive. In terms of
efficacy alone, the above regimen did not exceed Poticelli regimen. However, the toxic side
effects of rituximab, cyclosporine may be lower than that of Poticelli regimen. Based on the
preliminary experiment, this study explored a new treatment plan: low-dose rituximab combined
with cyclosporine in the treatment of IMN, the efficacy is not inferior to Poticelli regimen,
but the side effects are significantly reduced. The result will provide a good choice for IMN
patients.